	US 12,258,376 B2
	Fusion protein of DCTN1 protein with RET protein
Kohei Hayashi, Tsukuba (JP); and Keiji Ishida, Tsukuba (JP)
Assigned to TAIHO PHARMACEUTICAL CO., LTD., Tokyo (JP)
Appl. No. 16/640,955
Filed by TAIHO PHARMACEUTICAL CO., LTD., Tokyo (JP)
PCT Filed Aug. 20, 2018, PCT No. PCT/JP2018/030688 § 371(c)(1), (2) Date Feb. 21, 2020, PCT Pub. No. WO2019/039439, PCT Pub. Date Feb. 28, 2019.
Claims priority of application No. 2017-158796 (JP), filed on Aug. 21, 2017.
Prior Publication US 2020/0190154 A1, Jun. 18, 2020
Int. Cl. C07K 14/47 (2006.01); C07K 16/32 (2006.01); C12N 15/63 (2006.01); C12Q 1/6806 (2018.01); C12Q 1/6813 (2018.01); C12Q 1/6876 (2018.01)

CPC C07K 14/47 (2013.01) [C07K 16/32 (2013.01); C12N 15/63 (2013.01); C12Q 1/6806 (2013.01); C12Q 1/6813 (2013.01); C12Q 1/6876 (2013.01)]

1 Claim

1. A fused polypeptide wherein a polypeptide containing part of or the entire coiled-coil domain that is in an N-terminal portion of Dynactin Subunit 1 (DCTN1) protein is fused to a polypeptide containing a kinase domain that is in a C-terminal portion of Ret Proto-Oncogene protein (RET), which is:

a polypeptide comprising an amino acid sequence wherein one to ten amino acids are substituted, deleted, or added in the amino acid sequence represented by SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 24,

wherein the fused polypeptide comprises at least one protein tag selected from the group consisting of His tag, Myc tag, and FLAG tag.